Applied DNA Sciences (APDN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

APDN Stock Forecast

Applied DNA Sciences stock forecast is as follows: an average price target of $1.50 (represents a 784.96% upside from APDN’s last price of $0.17) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

APDN Price Target

The average price target for Applied DNA Sciences (APDN) is $1.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential 784.96% upside from APDN's last price of $0.17.

APDN Analyst Ratings

Buy

According to 1 Wall Street analysts, Applied DNA Sciences's rating consensus is 'Buy'. The analyst rating breakdown for APDN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Applied DNA Sciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 10, 2024	Yi Chen	H.C. Wainwright	$1.50	$0.54	179.80%	784.96%
Aug 08, 2022	-	H.C. Wainwright	$8.00	$5.82	37.54%	4619.76%
May 16, 2022	-	H.C. Wainwright	$4.00	$1.40	185.71%	2259.88%

Row per page

Go to

The latest Applied DNA Sciences stock forecast, released on Jun 10, 2024 by Yi Chen from H.C. Wainwright, set a price target of $1.50, which represents a 179.80% increase from the stock price at the time of the forecast ($0.54), and a 784.96% increase from APDN last price ($0.17).

Applied DNA Sciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$1.50
Last Closing Price	$0.17	$0.17	$0.17
Upside/Downside	-100.00%	-100.00%	784.96%

In the current month, the average price target of Applied DNA Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Applied DNA Sciences's last price of $0.17. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 10, 2024	H.C. Wainwright	Buy	Buy	Hold

Row per page

Go to

Applied DNA Sciences's last stock rating was published by H.C. Wainwright on Jun 10, 2024. The company gave APDN a "Buy" rating, the same as its previous rate.

Applied DNA Sciences Financial Forecast

Applied DNA Sciences Revenue Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
Revenue	-	-	-	-	-	-	-	$891.16K	$779.74K	$2.92M	$4.41M	$5.26M	$3.56M	$4.30M	$6.15M	$4.17M	$3.04M	$1.70M	$2.67M	$1.62M	$313.99K	$431.52K	$552.47K	$633.52K	$1.67M	$2.05M	$778.47K	$1.04M	$905.37K	$573.32K
Avg Forecast	$1.71M	$1.46M	$1.10M	$1.04M	$899.00K	$1.08M	$951.00K	$776.00K	$1.68M	$2.56M	$4.13M	$4.17M	$4.10M	$3.60M	$4.50M	$4.04M	$2.30M	$3.13M	$2.60M	$1.36M	$707.50K	$802.00K	$946.00K	$747.00K	$2.11M	$3.54M	$1.32M	$1.78M	$910.00K	$447.86K
High Forecast	$1.71M	$1.46M	$1.10M	$1.04M	$899.00K	$1.08M	$951.00K	$776.00K	$1.68M	$2.56M	$4.13M	$4.17M	$4.10M	$3.60M	$4.50M	$4.04M	$2.30M	$3.13M	$2.60M	$1.36M	$707.50K	$802.00K	$946.00K	$747.00K	$2.11M	$3.54M	$1.32M	$2.14M	$1.09M	$537.43K
Low Forecast	$1.71M	$1.46M	$1.10M	$1.04M	$899.00K	$1.08M	$951.00K	$776.00K	$1.68M	$2.56M	$4.13M	$4.17M	$4.10M	$3.60M	$4.50M	$4.04M	$2.30M	$3.13M	$2.60M	$1.36M	$707.50K	$802.00K	$946.00K	$747.00K	$2.11M	$3.54M	$1.32M	$1.43M	$728.00K	$358.28K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	9	6	4	4	7	4	11	9	20
Surprise %	-	-	-	-	-	-	-	1.15%	0.46%	1.14%	1.07%	1.26%	0.87%	1.19%	1.37%	1.03%	1.32%	0.54%	1.03%	1.19%	0.44%	0.54%	0.58%	0.85%	0.79%	0.58%	0.59%	0.59%	0.99%	1.28%

Applied DNA Sciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $951.00K, with a low forecast of $951.00K, and a high forecast of $951.00K. APDN's average Quarter revenue forecast represents a 6.71% increase compared to the company's last Quarter revenue of $891.16K (Dec 23).

Applied DNA Sciences EBITDA Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	9	6	4	4	7	4	11	9	20
EBITDA	-	-	-	-	-	-	-	$-3.79M	$-3.41M	$-2.86M	$-5.61M	$1.76M	$-8.91M	$-4.27M	$-2.06M	$-4.31M	$-2.51M	$-3.12M	$-2.96M	$-1.10M	$-4.01M	$-3.20M	$-2.86M	$-2.54M	$-1.79M	$-1.34M	$-2.53M	$-1.99M	$-3.26M	$-3.28M
Avg Forecast	$-1.51M	$-1.29M	$-972.70K	$-916.19K	$-793.88K	$-952.83K	$-839.80K	$-685.26K	$-1.48M	$-2.26M	$-3.64M	$-3.68M	$-3.93M	$-3.44M	$-1.87M	$-3.86M	$-2.20M	$-2.99M	$-1.32M	$-1.30M	$-676.57K	$-766.94K	$-2.78M	$-714.34K	$-2.02M	$-3.38M	$-2.88M	$-2.55M	$-3.27M	$-2.40M
High Forecast	$-1.51M	$-1.29M	$-972.70K	$-916.19K	$-793.88K	$-952.83K	$-839.80K	$-685.26K	$-1.48M	$-2.26M	$-3.64M	$-3.68M	$-3.93M	$-3.44M	$-1.49M	$-3.86M	$-2.20M	$-2.99M	$-1.05M	$-1.30M	$-676.57K	$-766.94K	$-2.23M	$-714.34K	$-2.02M	$-3.38M	$-2.30M	$-2.04M	$-2.61M	$-1.92M
Low Forecast	$-1.51M	$-1.29M	$-972.70K	$-916.19K	$-793.88K	$-952.83K	$-839.80K	$-685.26K	$-1.48M	$-2.26M	$-3.64M	$-3.68M	$-3.93M	$-3.44M	$-2.24M	$-3.86M	$-2.20M	$-2.99M	$-1.58M	$-1.30M	$-676.57K	$-766.94K	$-3.34M	$-714.34K	$-2.02M	$-3.38M	$-3.45M	$-3.06M	$-3.92M	$-2.88M
Surprise %	-	-	-	-	-	-	-	5.53%	2.29%	1.27%	1.54%	-0.48%	2.27%	1.24%	1.11%	1.12%	1.14%	1.04%	2.24%	0.85%	5.93%	4.17%	1.03%	3.55%	0.89%	0.40%	0.88%	0.78%	1.00%	1.37%

1 analysts predict APDN's average Quarter EBITDA for Mar 23 to be $-3.64M, with a high of $-3.64M and a low of $-3.64M. This is -307.26% lower than Applied DNA Sciences's previous annual EBITDA (Dec 22) of $1.76M.

Applied DNA Sciences Net Income Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	9	6	4	4	7	4	11	9	20
Net Income	-	-	-	-	-	-	-	$-1.18M	$-3.59M	$-3.10M	$588.34K	$-3.84M	$-773.07K	$-1.12M	$-1.13M	$-4.81M	$-6.20M	$-3.53M	$122.06K	$-8.41M	$-4.12M	$-3.29M	$-2.95M	$-2.71M	$-1.23M	$-1.52M	$-2.74M	$-2.15M	$-3.44M	$-3.49M
Avg Forecast	$-903.21K	$-943.35K	$-1.12M	$-1.30M	$-1.36M	$-1.99M	$-18.06M	$-24.89M	$-21.28M	$-19.27M	$-16.06M	$-23.28M	$-18.87M	$-28.50M	$-2.29M	$-21.41M	$-29.97M	$-21.14M	$-1.52M	$-43.35M	$-41.75M	$-54.19M	$-2.88M	$-99.55M	$-101.16M	$-48.17M	$-2.99M	$-2.74M	$-3.43M	$-2.52M
High Forecast	$-903.21K	$-943.35K	$-1.12M	$-1.30M	$-1.36M	$-1.99M	$-18.06M	$-24.89M	$-21.28M	$-19.27M	$-16.06M	$-23.28M	$-18.87M	$-28.50M	$-1.83M	$-21.41M	$-29.97M	$-21.14M	$-1.21M	$-43.35M	$-41.75M	$-54.19M	$-2.30M	$-99.55M	$-101.16M	$-48.17M	$-2.39M	$-2.19M	$-2.74M	$-2.02M
Low Forecast	$-903.21K	$-943.35K	$-1.12M	$-1.30M	$-1.36M	$-1.99M	$-18.06M	$-24.89M	$-21.28M	$-19.27M	$-16.06M	$-23.28M	$-18.87M	$-28.50M	$-2.75M	$-21.41M	$-29.97M	$-21.14M	$-1.82M	$-43.35M	$-41.75M	$-54.19M	$-3.45M	$-99.55M	$-101.16M	$-48.17M	$-3.58M	$-3.28M	$-4.11M	$-3.03M
Surprise %	-	-	-	-	-	-	-	0.05%	0.17%	0.16%	-0.04%	0.17%	0.04%	0.04%	0.49%	0.22%	0.21%	0.17%	-0.08%	0.19%	0.10%	0.06%	1.03%	0.03%	0.01%	0.03%	0.92%	0.79%	1.00%	1.38%

Applied DNA Sciences's average Quarter net income forecast for Jun 23 is $-19.27M, with a range of $-19.27M to $-19.27M. APDN's average Quarter net income forecast represents a -3375.04% decrease compared to the company's last Quarter net income of $588.34K (Mar 23).

Applied DNA Sciences SG&A Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	9	6	4	4	7	4	11	9	20
SG&A	-	-	-	-	-	-	-	$3.08M	$3.31M	$3.29M	$3.52M	$2.63M	$3.87M	$3.01M	$3.41M	$4.66M	$2.31M	$3.24M	$3.56M	$3.50M	$2.89M	$2.59M	$2.29M	$2.37M	$2.26M	$2.41M	$2.53M	$2.00M	$3.23M	$3.12M
Avg Forecast	$3.53M	$3.01M	$2.28M	$2.15M	$1.86M	$2.23M	$1.97M	$1.60M	$3.47M	$5.29M	$8.53M	$8.62M	$8.49M	$7.45M	$4.45M	$8.34M	$4.75M	$6.47M	$5.38M	$2.81M	$1.46M	$1.66M	$1.96M	$1.54M	$4.37M	$7.31M	$2.73M	$3.69M	$1.88M	$925.97K
High Forecast	$3.53M	$3.01M	$2.28M	$2.15M	$1.86M	$2.23M	$1.97M	$1.60M	$3.47M	$5.29M	$8.53M	$8.62M	$8.49M	$7.45M	$5.34M	$8.34M	$4.75M	$6.47M	$5.38M	$2.81M	$1.46M	$1.66M	$1.96M	$1.54M	$4.37M	$7.31M	$2.73M	$4.42M	$2.26M	$1.11M
Low Forecast	$3.53M	$3.01M	$2.28M	$2.15M	$1.86M	$2.23M	$1.97M	$1.60M	$3.47M	$5.29M	$8.53M	$8.62M	$8.49M	$7.45M	$3.56M	$8.34M	$4.75M	$6.47M	$5.38M	$2.81M	$1.46M	$1.66M	$1.96M	$1.54M	$4.37M	$7.31M	$2.73M	$2.95M	$1.51M	$740.77K
Surprise %	-	-	-	-	-	-	-	1.92%	0.95%	0.62%	0.41%	0.30%	0.46%	0.40%	0.77%	0.56%	0.49%	0.50%	0.66%	1.25%	1.98%	1.56%	1.17%	1.54%	0.52%	0.33%	0.93%	0.54%	1.72%	3.37%

Applied DNA Sciences's average Quarter SG&A projection for Mar 24 is $1.97M, based on 1 Wall Street analysts, with a range of $1.97M to $1.97M. The forecast indicates a -36.25% fall compared to APDN last annual SG&A of $3.08M (Dec 23).

Applied DNA Sciences EPS Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	9	6	4	4	7	4	11	9	20
EPS	-	-	-	-	-	-	-	$-0.09	$-0.27	$-0.24	$0.05	$-0.30	$-0.09	$-0.13	$-0.14	$-0.64	$-0.83	$-0.47	$-0.21	$-1.54	$-0.76	$-0.72	$-0.79	$-1.14	$-0.52	$-1.60	$-3.28	$-2.86	$-5.22	$-5.80
Avg Forecast	$-0.23	$-0.23	$-0.28	$-0.33	$-0.34	$-0.49	$-4.50	$-6.20	$-5.30	$-4.80	$-4.00	$-5.80	$-4.70	$-7.10	$-6.67	$-5.33	$-7.47	$-5.27	$-4.27	$-10.80	$-10.40	$-13.50	$-15.40	$-24.80	$-25.20	$-12.00	$-48.00	$-6.12	$-0.13	$-0.08
High Forecast	$-0.23	$-0.23	$-0.28	$-0.33	$-0.34	$-0.49	$-4.50	$-6.20	$-5.30	$-4.80	$-4.00	$-5.80	$-4.70	$-7.10	$-6.67	$-5.33	$-7.47	$-5.27	$-4.27	$-10.80	$-10.40	$-13.50	$-15.40	$-24.80	$-25.20	$-12.00	$-48.00	$-4.90	$-0.10	$-0.06
Low Forecast	$-0.23	$-0.23	$-0.28	$-0.33	$-0.34	$-0.49	$-4.50	$-6.20	$-5.30	$-4.80	$-4.00	$-5.80	$-4.70	$-7.10	$-6.67	$-5.33	$-7.47	$-5.27	$-4.27	$-10.80	$-10.40	$-13.50	$-15.40	$-24.80	$-25.20	$-12.00	$-48.00	$-7.34	$-0.16	$-0.10
Surprise %	-	-	-	-	-	-	-	0.01%	0.05%	0.05%	-0.01%	0.05%	0.02%	0.02%	0.02%	0.12%	0.11%	0.09%	0.05%	0.14%	0.07%	0.05%	0.05%	0.05%	0.02%	0.13%	0.07%	0.47%	40.15%	72.50%

According to 1 Wall Street analysts, Applied DNA Sciences's projected average Quarter EPS for Jun 23 is $-4.80, with a low estimate of $-4.80 and a high estimate of $-4.80. This represents a -9700.00% decrease compared to APDN previous annual EPS of $0.05 (Mar 23).

Applied DNA Sciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DRIO	DarioHealth	$0.80	$10.75	1243.75%	Buy
STIM	Neuronetics	$0.78	$8.00	925.64%	Buy
APDN	Applied DNA Sciences	$0.17	$1.50	782.35%	Buy
OCX	OncoCyte	$2.63	$8.08	207.22%	Buy
GTH	Genetron	$4.03	$10.00	148.14%	-
BDSX	Biodesix	$1.26	$3.00	138.10%	Buy
PSNL	Personalis	$3.59	$7.75	115.88%	Hold
XGN	Exagen	$3.00	$5.00	66.67%	Buy
OLK	Olink AB (publ)	$26.08	$21.50	-17.56%	Hold

APDN Forecast FAQ

Is Applied DNA Sciences a good buy?

Yes, according to 1 Wall Street analysts, Applied DNA Sciences (APDN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of APDN's total ratings.

What is APDN's price target?

Applied DNA Sciences (APDN) average price target is $1.5 with a range of $1.5 to $1.5, implying a 784.96% from its last price of $0.17. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Applied DNA Sciences stock go up soon?

According to Wall Street analysts' prediction for APDN stock, the company can go up by 784.96% (from the last price of $0.17 to the average price target of $1.5), up by 784.96% based on the highest stock price target, and up by 784.96% based on the lowest stock price target.

Can Applied DNA Sciences stock reach $0?

APDN's average twelve months analyst stock price target of $1.5 supports the claim that Applied DNA Sciences can reach $0 in the near future.

What are Applied DNA Sciences's analysts' financial forecasts?

Applied DNA Sciences's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $3.7M (high $3.7M, low $3.7M), average EBITDA is $-3.272M (high $-3.272M, low $-3.272M), average net income is $-46.305M (high $-46.305M, low $-46.305M), average SG&A $7.66M (high $7.66M, low $7.66M), and average EPS is $-11.535 (high $-11.535, low $-11.535). APDN's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $5.3M (high $5.3M, low $5.3M), average EBITDA is $-4.684M (high $-4.684M, low $-4.684M), average net income is $-4.275M (high $-4.275M, low $-4.275M), average SG&A $10.97M (high $10.97M, low $10.97M), and average EPS is $-1.065 (high $-1.065, low $-1.065).

Did the APDN's actual financial results beat the analysts' financial forecasts?

Based on Applied DNA Sciences's last annual report (Sep 2023), the company's revenue was $13.37M, beating the average analysts forecast of $12.53M by 6.66%. Apple's EBITDA was $-10.953M, missing the average prediction of $-11.068M by -1.03%. The company's net income was $-9.947M, missing the average estimation of $-79.884M by -87.55%. Apple's SG&A was $12.75M, missing the average forecast of $25.91M by -50.79%. Lastly, the company's EPS was $-0.76, missing the average prediction of $-19.9 by -96.18%. In terms of the last quarterly report (Dec 2023), Applied DNA Sciences's revenue was $891.16K, beating the average analysts' forecast of $776K by 14.84%. The company's EBITDA was $-3.789M, beating the average prediction of $-685K by 452.94%. Applied DNA Sciences's net income was $-1.183M, missing the average estimation of $-24.888M by -95.25%. The company's SG&A was $3.08M, beating the average forecast of $1.6M by 92.24%. Lastly, the company's EPS was $-0.0865, missing the average prediction of $-6.2 by -98.60%